|
Search
Collections
Benchmarks
Upload document
Target
CELMoD
Rename entity
Add alias
Merge entity
Delete entity
Embed entity
1 abstract
Abstract
MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM).
Org:
Pfizer Oncology Division,
